The global peptide drug conjugates industry is expected to be worth US$ 861.12 million in 2023 and US$ 5,331.83 million by 2033. Over the forecast period of 2023 to 2033, the predicted growth rate is about 20%. The growth of the market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.
The Peptide Drug Conjugates Industry refers to the pharmaceutical sector focused on the development and commercialization of therapeutic compounds that combine peptides with other molecules, such as small molecules or antibodies. These conjugates offer targeted delivery and enhanced therapeutic efficacy for a wide range of diseases, including cancer, metabolic disorders, and infectious diseases.
To Remain Ahead of Your Competitors, Request For A Sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-15939
The PDC market has been gaining significant attention in recent years due to the potential advantages offered by these compounds. By attaching a peptide to a drug or a targeting moiety, PDCs can specifically target diseased cells or tissues, improving the drug’s efficacy and reducing side effects. This targeted approach allows for more precise treatment, leading to better patient outcomes.
The market for PDCs has been growing steadily, driven by factors such as increasing prevalence of chronic diseases, advancements in peptide synthesis and conjugation technologies, and the demand for personalized medicine. Additionally, the rising interest in biologics and the development of novel peptide-based therapies have further propelled the growth of the PDC market.
Key Takeaways from the Market Study:
- By product, Lutathera segment accounted for the largest share of 80.5% in 2022
- Based on type, therapeutic segment dominated the Peptide Drug Conjugates Industry with the revenue share of 82.3%.
- North America dominated the global market in 2022 with a revenue share of 45.62%.
- Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period.
“Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth.,” says an analyst at Future Market Insights.
Our Analyst Is Available To Help You With Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-15939
Key Market Players:
Major players are channelling efforts toward expanding their production capacities to strengthen their market share and cater to the growing demand. Market expansion is anticipated to be aided by the growing number of partnerships and collaborations among key players that are looking to increase their presence in the market. Key players in the Peptide Drug Conjugates Industry are:
- Novartis AG
- Oncopeptides AB
- Bicycle Therapeutics
- AstraZeneca
- Cybrexa Therapeutics
- Angiochem Inc.
- Innovasium Soricimed Biopharma
- Theratechnologies
- Coherent Biopharma
- WuXI STA
In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for targeted drug therapy.
In December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
Customization Unleashed: Learn How to Stand Out in a Competitive Landscape! https://www.futuremarketinsights.com/customization-available/rep-gb-15939
More Valuable Insights:
Future Market Insights, in its new offering, presents an unbiased analysis of the global Peptide Drug Conjugates Industry, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Key Market Segments Covered in the Global Peptide Drug Conjugates Industry:
By Product:
- Lutetium
- Melflufen
- ANG1005
- BT1718
- CBX-12
- Other Pipeline Products
By Type:
- Therapeutic Peptide Drug Conjugates
- Diagnostic Peptide Drug Conjugates
By Region:
- North America Peptide Drug Conjugates Industry
- Latin America Peptide Drug Conjugates Industry
- Europe Peptide Drug Conjugates Industry
- Asia Pacific Peptide Drug Conjugates Industry
- Middle East & Africa Peptide Drug Conjugates Industry
Gain Immediate Access to Detailed Market Insights: Purchase Now! https://www.futuremarketinsights.com/checkout/15939
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
